mepa8 Get alerts

About one in 10 US adults took a GLP-1 drug in the past year, CDC survey finds

Among users, about one in five reported taking a compounded version and about two in five changed how they took the drug, often citing cost and availability.

Mepa8 headline card: About one in 10 US adults took a GLP-1 drug in the past year, CDC survey finds

Key takeaways

  • A CDC MMWR report dated Nov. 12, 2026, finds about one in 10 US adults reported taking a GLP-1 medication in the prior year, based on a July–August 2025 survey.
  • About one in five GLP-1 users reported taking a compounded version, which the report says FDA does not review for safety, effectiveness or quality before marketing.
  • About two in five users said they modified their use from the way it was prescribed, often citing cost and availability as barriers.
  • The survey had 8,118 completed responses, and 976 adults who reported GLP-1 use answered follow-up questions.
  • For crews: the report's screening question names Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta and Bydureon BCise as GLP-1 brands.

A CDC report published November 12, 2026, in the Morbidity and Mortality Weekly Report finds that roughly one in 10 US adults said they took a glucagon-like peptide-1 (GLP-1) medication in the past year. [1]

The report, by Samantha L. Pierce and colleagues at CDC, draws on data from the agency's Rapid Surveys System collected during July–August 2025. Among adults who reported GLP-1 use, about one in five said they took a compounded version. About two in five said they changed how they used the medication from the way it was prescribed. [1]

The authors wrote that respondents who modified their use were "often citing cost and availability as barriers." The report states that compounded GLP-1 products do not go through FDA review for safety, effectiveness or quality before they reach the market. [1]

What the records show

The survey was Round 7 of the Rapid Surveys System. It used two online probability panels: the NORC AmeriSpeak Panel at the University of Chicago and Ipsos's KnowledgePanel. Sampling weights were calibrated to National Health Interview Survey population totals to produce national estimates. The survey completion rate was 62.6%, yielding 8,118 completed surveys. Cumulative panel response rates were 13.3% for AmeriSpeak and 3.8% for KnowledgePanel. [1]

All respondents were asked one screening question: "In the past 12 months, have you taken an oral or injectable medication for diabetes or weight loss, such as Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta, or Bydureon BCise?" The question added that these drugs may contain semaglutide, tirzepatide, liraglutide, dulaglutide or exenatide. [1]

The 976 adults who reported use received follow-up questions about compounded products and about changes to how they took the drug, with skipping doses given as an example. The authors calculated weighted prevalence estimates with 95% confidence intervals overall and by sex, age group, race and ethnicity, body mass index category, insurance type, household income and urbanicity. [1]

The report's summary gives these headline findings:

  • About one in 10 adults reported GLP-1 medication use in the past year.
  • About one in five users reported taking a compounded version.
  • About two in five users reported modifying their medication use, often because of cost and availability.

The abstract adds that modifications were seen "particularly among younger adults." [1]

Why it matters for clinicians

The report frames the findings as evidence of a shift in how chronic disease is treated. The authors wrote that the prevalence of use "highlights the expanded role of these medications in chronic disease pharmacotherapy." [1]

Several findings bear on patient encounters. A share of patients who report GLP-1 use may be taking compounded products. The report says these products contain the same active ingredients as approved versions but may contain additional unregulated ingredients. It also says they may be marketed inaccurately, including without disclosure of possible adverse effects. Separately, the authors wrote that patient-made dose and frequency adjustments "might have implications for safety and effectiveness." The report does not quantify any harm from either practice. [1]

The screening question itself lists the brand names and active ingredients patients are likely to recognize, which gives clinicians a reference for what a patient may mean when describing a diabetes or weight-loss injection. [1]

Context

The report's introduction cites prior national estimates. Approximately 100 million US adults, or 40%, have obesity, including approximately 22 million (9%) with severe obesity. Approximately 29 million US adults have diagnosed diabetes. Among those adults, 88% have overweight or obesity, and 67% have high blood pressure or take blood pressure medication. [1]

FDA approved semaglutide for chronic weight management in 2021 and tirzepatide in 2023. The authors say those approvals produced a substantial rise in prescriptions, followed by problems with high costs, drug shortages and limited insurance coverage. The report cites a separate study covering 2022–2024 in which approximately one half of adults with overweight or obesity, but not diabetes, who started a GLP-1 stopped because of cost or insurance problems. Another 12% could not fill prescriptions because of shortages. During earlier shortages, the authors wrote, compounded GLP-1 products became broadly available as alternatives. [1]

What the records do not tell us

  • The available text of the report ends partway through the methods section. Exact weighted percentages, confidence intervals and subgroup results by age, sex, race and ethnicity, insurance type or income are not in the records.
  • The report does not state which kinds of modification were most common beyond giving skipped doses as an example.
  • The survey relies on self-report through online panels. The records do not describe any verification of prescriptions or identify which compounded products respondents used.
  • The records do not report adverse events, hospital visits or EMS encounters linked to compounded products or modified dosing.
  • The records state the panel response rates but do not discuss how nonresponse may have affected the estimates beyond the use of calibrated weights.
  • The records do not say whether CDC plans a follow-up survey round on GLP-1 use.

Questions readers ask

How many US adults use GLP-1 medications?

A CDC report published November 12, 2026, found that approximately one in 10 US adults reported taking a GLP-1 medication in the past year. The estimate comes from the Rapid Surveys System, which collected 8,118 completed surveys during July–August 2025.

What share of GLP-1 users take compounded versions?

Among adults who reported GLP-1 use, approximately one in five said they took a compounded version, according to the CDC report. Compounded GLP-1 medications are not reviewed by FDA for safety, effectiveness or quality before they are marketed.

Why do people change how they take GLP-1 medications?

The CDC report found that approximately two in five GLP-1 users modified their use from the way it was prescribed. The authors wrote that respondents often cited cost and availability as barriers, and that modifications were seen particularly among younger adults.

Which drugs count as GLP-1 medications in the CDC survey?

The survey question named Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta and Bydureon BCise. It said these medications may contain semaglutide, tirzepatide, liraglutide, dulaglutide or exenatide.

Sources

  1. CDC MMWR, Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025 (Nov. 12, 2026) — tools.cdc.gov (2026-11-12). tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=766820
How this story was made Drafted by Mepa8's AI newsroom from the 1 record listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me